Uni-Bio Partners with DotBio to Develop Retinal Therapeutics

Yangzhou Uni-Bio formed a partnership with Singapore 's DotBio to co-develop next-gen, best-in-class synthetic retinal therapeutics. The companies will use the DotBody platform to generate multiple multi-valent and/or bi-specific stabilized and single-domain antibody candidates to discover therapies for conditions that cause visual impairment or blindness globally. Uni-Bio will be responsible for R&D of the candidates, clinical trials and commercialization. DotBio will receive upfront and research payments, plus milestones and royalties. More details.... Stock Symbol: (HK: 00690) Share this with colleagues: // //